Evidence for Seroprevalence in Human Localized Cutaneous Leishmaniasis Caused by Leishmania donovani in Sri Lanka

Table 2

Serological response according to different clinical features.

Clinical feature and category	Seropositive patients (n); (% within category)	Seronegative patients (n); (% within category)	Total (n); (% within category)
Originating province
Northern	6 (42.9%)	8 (57.1%)	14 (100%)
Southern	9 (36.0%)	16 (64.0%)	25 (100%)
Other	2 (18.2%)	9 (81.8%)	11 (100%)
Total	17 (34.0%)	33 (66.0%)	50 (100%)
Occupation
Military	6 (30.0%)	14 (70.0%)	20 (100%)
Civilian	11 (39.3%)	17 (60.7%)	28 (100%)
Total	17 (35.4%)	31 (64.6%)	48 (100%)
Age
Up to 20 years	3 (37.5%)	5 (62.5%)	8 (100%)
21–40 years	9 (39.1%)	14 (60.9%)	23 (100%)
>41 years	5 (26.3%)	14 (73.7%)	19 (100%)
Total	17 (34.0%)	33 (66.0%)	50 (100%)
Sex
Male	13 (32.5%)	27 (67.5%)	40 (100%)
Female	4 (40.0%)	6 (60.0%)	10 (100%)
Total	17 (34.0%)	33 (66.0%)	50 (100%)
Number of lesions
Single	14 (37.8%)	23 (62.2%)	37 (100%)
Multiple	3 (23.1%)	10 (76.9%)	13 (100%)
Total	17 (34.0%)	33 (66.0%)	50 (100%)
Size of the lesions
Up to 2 cm	14 (46.7%)	25 (53.3%)	39 (100%)
>2 cm	3 (27.2%)	8 (72.8%)	11 (100%)
Total	17 (34.0%)	33 (66.0%)	50 (100%)
Duration
Up to 3 months	4 (30.8%)	9 (69.2%)	13 (100%)
3–6 months	7 (36.8%)	12 (63.2%)	19 (100%)
7–9 months	2 (28.6%)	5 (71.4%)	7 (100%)
10–12 months	4 (36.4%)	7 (63.6%)	11 (100%)
Total	17 (34.0%)	33 (66.0%)	50 (100%)
Type of lesion
Papule	1 (25.0%)	3 (75.0%)	4 (100%)
Nodule	8 (47.1%)	9 (52.9%)	17 (100%)
Ulcerating nodule	4 (30.8%)	9 (69.2%)	13 (100%)
Ulcer	3 (30.0%)	7 (70.0%)	10 (100%)
Plaque	1 (16.7%)	5 (83.3%)	11 (100%)
Total	17 (34.0%)	33 (66.0%)	50 (100%)

Missing cases excluded.